Encorafenib
Sign in to save this workspacePrimary targets: BRAF · FDA status: FDA Approved
Selectivity scorecard
KISS
98.50
Gini
0.755
CATDS
0.029
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Encorafenib. Strongest target: RAF1 at 99.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RAF1 | 99.7% | 0.3% |
| 2 | BRAF | 98.0% | 2.0% |
| 3 | IRAK1 | 97.5% | 2.5% |
| 4 | ARAF | 97.4% | 2.6% |
| 5 | LIMK2 | 93.9% | 6.1% |
| 6 | GSK3B | 91.5% | 8.5% |
| 7 | LIMK1 | 88.5% | 11.5% |
| 8 | JNK3 | 82.1% | 17.9% |
| 9 | RIPK3 | 76.6% | 23.4% |
| 10 | NLK | 71.3% | 28.6% |
| 11 | JNK1 | 69.9% | 30.1% |
| 12 | JNK2 | 65.6% | 34.4% |
| 13 | ZAK_MLTK | 63.5% | 36.5% |
| 14 | MLK2_MAP3K10 | 62.1% | 37.9% |
| 15 | HIPK4 | 54.2% | 45.8% |
| 16 | P38A_MAPK14 | 53.5% | 46.5% |
| 17 | CK1G2 | 52.6% | 47.4% |
| 18 | TESK2 | 52.3% | 47.7% |
| 19 | PDK2_PDHK2 | 48.5% | 51.5% |
| 20 | MKK6 | 48.4% | 51.6% |
Selectivity landscape
Where Encorafenib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Encorafenib.
Atlas insights for Encorafenib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target2%
Off-target98%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1885.33 | |
| ALLOGRAFT_REJECTION | 2366.36 | |
| ANDROGEN_RESPONSE | 1600.58 | |
| ANGIOGENESIS | 323.46 | |
| APICAL_JUNCTION | 2416.73 | |
| APICAL_SURFACE | 351.99 | |
| APOPTOSIS | 4542.50 | |
| BILE_ACID_METABOLISM | 420.57 | |
| CHOLESTEROL_HOMEOSTASIS | 375.33 | |
| COAGULATION | 338.04 | |
| COMPLEMENT | 1886.78 | |
| DNA_REPAIR | 1555.13 | |
| E2F_TARGETS | 4580.13 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1543.90 | |
| ESTROGEN_RESPONSE_EARLY | 2358.24 | |
| ESTROGEN_RESPONSE_LATE | 2208.10 | |
| FATTY_ACID_METABOLISM | 375.89 | |
| G2M_CHECKPOINT | 4913.97 | |
| GLYCOLYSIS | 1191.65 | |
| HEDGEHOG_SIGNALING | 402.30 | |
| HEME_METABOLISM | 1712.27 | |
| HYPOXIA | 2525.57 | |
| IL2_STAT5_SIGNALING | 2151.15 | |
| IL6_JAK_STAT3_SIGNALING | 1469.37 | |
| INFLAMMATORY_RESPONSE | 2471.10 | |
| INTERFERON_ALPHA_RESPONSE | 528.23 | |
| INTERFERON_GAMMA_RESPONSE | 2723.74 | |
| KRAS_SIGNALING_DN | 785.53 | |
| KRAS_SIGNALING_UP | 1163.58 | |
| MITOTIC_SPINDLE | 3079.16 | |
| MTORC1_SIGNALING | 1982.55 | |
| MYC_TARGETS_V1 | 2824.49 | |
| MYC_TARGETS_V2 | 698.95 | |
| MYOGENESIS | 2199.02 | |
| NOTCH_SIGNALING | 380.87 | |
| OXIDATIVE_PHOSPHORYLATION | 384.72 | |
| P53_PATHWAY | 2895.45 | |
| PANCREAS_BETA_CELLS | 518.88 | |
| PEROXISOME | 739.40 | |
| PI3K_AKT_MTOR_SIGNALING | 4393.26 | |
| PROTEIN_SECRETION | 889.46 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 398.64 | |
| SPERMATOGENESIS | 1211.05 | |
| TGF_BETA_SIGNALING | 1697.35 | |
| TNFA_SIGNALING_VIA_NFKB | 3950.03 | |
| UNFOLDED_PROTEIN_RESPONSE | 902.33 | |
| UV_RESPONSE_DN | 3025.71 | |
| UV_RESPONSE_UP | 1988.08 | |
| WNT_BETA_CATENIN_SIGNALING | 1506.90 | |
| XENOBIOTIC_METABOLISM | 771.15 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.863 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.846 |
| SRR1443713 | GTEX | 0.842 |
| SRR12202498 | — | 0.841 |
| SRR1311182 | GTEX | 0.824 |
Annotations
Sign in to read and post annotations.
Loading…